Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Lymphoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Late effects of treatment of non-Hodgkin lymphoma (NHL) have been observed. Impaired fertility may occur after exposure to alkylating agents.[8] For as many as three decades after diagnosis, patients are at a significantly elevated risk of developing second primary cancers, especially the following:[9-12]
Lung cancer.
Brain cancer.
Kidney cancer.
Bladder cancer.
Melanoma.
Hodgkin lymphoma.
Acute nonlymphocytic leukemia.
Left ventricular dysfunction was a significant late effect in long-term survivors of high-grade NHL who received more than 200 mg/m² of doxorubicin.[8,13]
Myelodysplastic syndrome and acute myelogenous leukemia are late complications of myeloablative therapy with autologous bone marrow or peripheral blood stem cell support, as well as conventional chemotherapy-containing alkylating agents.[10,14-21] Most of these patients show clonal hematopoiesis even before the transplant, suggesting that the hematologic injury usually occurs during induction or reinduction chemotherapy.[16,22,23] A series of 605 patients who received autologous bone marrow transplant (BMT) with cyclophosphamide and total-body radiation therapy (as conditioning) were followed for a median of 10 years. The incidence of a second malignancy was 21%, and 10% of those malignancies were solid tumors.[24]
A study of young women who received autologous BMT reported successful pregnancies with children born free of congenital abnormalities.[25] Late-occurring venous thromboembolism can occur after allogeneic or autologous BMT.[26]
Some patients have osteopenia or osteoporosis at the start of therapy; bone density may worsen after therapy for lymphoma.[27]
Sources: 27
Long-term impaired immune health was evaluated in a retrospective cohort study of 21,690 survivors of diffuse large B-cell lymphoma from the California Cancer Registry. Elevated incidence rate ratios were found up to 10 years later for pneumonia (10.8-fold), meningitis (5.3-fold), immunoglobulin deficiency (17.6-fold), and autoimmune cytopenias (12-fold).[28] Similarly, there are impaired humoral responses to COVID-19 virus vaccination in patients with lymphoma who receive B-cell–directed therapies.[29,30]
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Because of the often-indolent clinical course and the lack of symptoms in some patients with follicular lymphoma, watchful waiting remains a standard of care during the initial encounter and for patients with slow asymptomatic relapsing disease. When therapy is required, numerous options may be used in varying sequences with an OS equivalence at 5 to 10 years.[9,21-23] Rituximab can be given alone or in combination with various chemotherapy options.[23-25] Rituximab can also be combined with the immunomodulating-agent lenalidomide to avoid the short- and long-term toxicities of cytotoxic agents.[26-28] Obinutuzumab is a completely humanized anti–CD20 monoclonal antibody that can be given alone or with combination chemotherapy. It may be especially useful for patients who develop severe allergic reactions to rituximab due to human antimouse antibodies.[29] CD19-directed chimeric antigen receptor T cells may be used in patients who have disease progression after two or more prior lines of therapy.[30] Mosunetuzumab, a bispecific CD20-directed CD3 T-cell engager, may also be used in this setting.[31] Consolidation therapy for relapsed disease after reinduction therapy using autologous stem cell transplant (SCT) or allogeneic SCT can be considered.[32]
Sources: 9 · 21 · 23 · 23 · 25 · 26 · 28 · 29 · 30 · 31 · 32
Outside the context of clinical trials, the use of measurable residual disease (MRD) testing has not been shown to be predictive in directing therapy for patients with follicular lymphoma. In retrospective analyses of two randomized prospective trials, while MRD negativity was prognostic of outcome, maintenance rituximab or obinutuzumab prolonged PFS the most among patients with MRD-negative disease.[33,34][Level of evidence C2] Stopping maintenance rituximab or obinutuzumab was not indicated in patients with MRD-negative disease, negating any possible change in therapy based on that status.
Sources: 33 · 34 · Level of evidence C2
Follicular lymphoma in situ and primary follicular lymphoma of the duodenum are particularly indolent variants that rarely progress or require therapy.[35,36] A so-called pediatric-type nodal follicular lymphoma has indolent behavior and rarely recurs; adult patients with this histological variant have disease characterized by a lack of BCL2 rearrangement in conjunction with a Ki-67 proliferation index greater than 30% and a localized stage I presentation.[37]
Patients with indolent lymphoma may experience a relapse with a more aggressive histology. If the clinical pattern of relapse suggests that the disease is behaving in a more aggressive manner, a biopsy can be performed, if feasible.[38] If disease conversion to a more aggressive histology is confirmed, therapy must change to a regimen applicable to that histological type.[39] Rapid growth or discordant growth between various disease sites may indicate a histological conversion.[38]
In a prospective nonrandomized study, at a median follow-up of 6.8 years, 379 of 2,652 patients (14%) subsequently transformed to a more aggressive histology after an initial diagnosis of follicular lymphoma.[40][Level of evidence C3] The median OS after subsequent transformation was 5 years. However, among 47 patients with evidence of transformation in conjunction with follicular lymphoma at the time of initial diagnosis, the OS was no worse than that of the nontransformed patients (5-year OS rate, 88%; 95% CI, 74%–95%).
Sources: 40 · Level of evidence C3
Grade 3b follicular lymphoma is managed similarly to DLBCL. For more information, see Aggressive B-Cell Non-Hodgkin Lymphoma Treatment.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The management of lymphoplasmacytic lymphoma is similar to that of other low-grade lymphomas, especially diffuse small lymphocytic lymphoma/chronic lymphocytic leukemia.[46-48] If the serum viscosity relative to water is greater than four, the patient may have symptoms of hyperviscosity. Plasmapheresis is useful for temporary, acute symptoms such as retinopathy, congestive heart failure, and central nervous system (CNS) dysfunction. It can also be combined with chemotherapy for prolonged disease control. Symptomatic patients with a serum viscosity of four or lower are usually treated with chemoimmunotherapy or biologically directed therapies. Therapy may be required to correct hemolytic anemia in patients with chronic cold agglutinin disease; rituximab, bendamustine, and steroids are often used.[44] Occasionally, a heated room is required for patients whose cold agglutinins become activated by even minor chilling. Sutimlimab, an immunoglobulin G4 monoclonal antibody that selectively inhibits the complement pathway at C15, can reduce hemolysis when therapies directed at the lymphoplasmacytic lymphoma are ineffective.[49]
First-line regimens include zanubrutinib (a Bruton tyrosine kinase [BTK] inhibitor), rituximab, and ibrutinib (another BTK inhibitor), rituximab alone, the nucleoside analogues, and alkylating agents, either as single agents or as part of combination chemotherapy.[50-53] In a randomized prospective trial, 150 symptomatic patients (including patients with previously untreated and relapsing disease) received either ibrutinib and rituximab or rituximab and a placebo. With a median follow-up of 50 months, the 4.5-year PFS rate was 68% in the ibrutinib-and-rituximab arm (95% CI, 55%–78%) and 25% in the rituximab-and-placebo arm (95% CI, 15%–37%) (hazard ratio [HR], 0.25; 95% CI, 0.15–0.42; P < .0001). The OS rate at 30 months was no different in the two arms (92%–94%).[52][Level of evidence B1] Zanubrutinib was compared with ibrutinib in a randomized prospective clinical trial of 164 patients with relapsed disease and 38 with previously untreated disease.[53] With a median follow-up of 44.4 months, the PFS rate was similar in both groups at 70% to 78% (HR, 0.63; 95% CI, 0.36–1.12), and the OS rate was similar in both groups at 85% to 87% (HR, 0.75; 95% CI, 0.36–1.59).[54] The zanubrutinib group had fewer cases of atrial fibrillation (11 vs. 1) and 50% fewer cases of hypertension (statistics not provided).[53][Level of evidence C3] BTK inhibition with ibrutinib allowed all 13 patients with cold-antibody–mediated autoimmune hemolytic anemia and acrocyanosis to attain clinical remission regardless of underlying pathology or MYD88 variant status.[55][Level of evidence C3]
Sources: 50 · 53 · 52 · Level of evidence B1 · 53 · 54 · 53 · Level of evidence C3 · 55 · Level of evidence C3
Previously untreated patients who received rituximab had response rates of 60% to 80%, but close monitoring of the serum IgM is required because of a sudden rise in this paraprotein at the start of therapy.[56-58][Level of evidence C3] The rise of IgM after rituximab can be avoided with the concomitant use of an alkylating agent, such as cyclophosphamide, or the proteosome inhibitors bortezomib or ixazomib.[44,59-61] A combination of bortezomib, dexamethasone, and rituximab has been used without causing IgM rebound.[62-64] Previously untreated patients with lymphoplasmacytic lymphoma who received the nucleoside analogues cladribine and fludarabine showed similar response rates.[51,65,66][Level of evidence C3] Patients who received single-agent alkylators, bendamustine, bortezomib, venetoclax, and combination chemotherapy with or without rituximab also showed similar response rates.[51,59,61,67-71][Level of evidence C3] In the rare case of lymphoplasmacytic lymphoma involving the CNS (Bing-Neel syndrome), ibrutinib resulted in an 85% response rate in an anecdotal series of 28 patients.[72][Level of evidence C3]
Sources: 56 · 58 · Level of evidence C3 · 44 · 59 · 61 · 62 · 64 · 51 · 65 · 66 · Level of evidence C3 · 51 · 59 · 61 · 67 · 71 · Level of evidence C3 · 72 · Level of evidence C3
Myeloablative therapy with autologous or allogeneic hematopoietic stem cell support is under clinical evaluation.[73-76] Candidates for this approach should avoid long-term use of alkylating agents or purine nucleoside analogues, which can deplete hematopoietic stem cells or predispose patients to myelodysplasia or acute leukemia.[56,77] After relapse from alkylating-agent therapy, 92 patients with lymphoplasmacytic lymphoma were randomly assigned to receive either fludarabine or cyclophosphamide, doxorubicin, and prednisone. Although relapse-free survival favored fludarabine (median duration of 19 months vs. 3 months; P < .01), no difference was observed in OS.[78][Level of evidence B1]
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment of indolent non-Hodgkin lymphoma (NHL) depends on the histological type and stage. Many of the improvements in survival have been made because of clinical trials that have attempted to improve on conventional or standard therapy.
In asymptomatic patients with indolent forms of advanced NHL, treatment may be deferred until the patient becomes symptomatic as the disease progresses. When treatment is deferred, the clinical course of patients with indolent NHL varies; frequent and careful observation is required so that effective treatment can be initiated when the clinical course of the disease accelerates. Some patients have a prolonged indolent course, but others have disease that rapidly evolves into more aggressive types of NHL that require immediate treatment.
Radiation techniques differ somewhat from those used in the treatment of Hodgkin lymphoma. The dose of radiation therapy usually varies from 25 Gy to 50 Gy and is dependent on factors that include the histological type of lymphoma, the patient’s stage and overall condition, the goal of treatment (curative or palliative), the proximity of sensitive surrounding organs, and whether the patient is being treated with radiation therapy alone or in combination with chemotherapy. Given the patterns of disease presentations and relapse, treatment may need to include unusual sites such as Waldeyer ring, epitrochlear nodes, or mesenteric nodes. The associated morbidity of the treatment must be considered carefully. Most patients who receive radiation are treated on only one side of the diaphragm. Localized presentations of extranodal NHL may be treated with involved-field techniques with significant (>50%) success.
In situations where mediastinal radiation therapy would encompass the left side of the heart or would increase breast cancer risk in young female patients, proton therapy may be considered to reduce radiation dose to organs at risk.[1] For more information, see the Superior Vena Cava Syndrome section in Cardiopulmonary Syndromes.
Sources: 1 · Superior Vena Cava Syndrome
| Stage | Treatment Options |
|---|---|
| CAR = chimeric antigen receptor; SCT = stem cell transplant. | |
| Indolent Stage I and Indolent, Contiguous Stage II B-cell NHL | Radiation therapy |
| Rituximab with or without chemotherapy | |
| Watchful waiting | |
| Other therapies as designated for patients with advanced-stage disease | |
| Indolent, Noncontiguous Stage II/III/IV B-cell NHL | Watchful waiting for asymptomatic patients |
| Rituximab alone or in combination with cytotoxic agents used in front-line therapy | |
| Lenalidomide and rituximab | |
| Maintenance rituximab | |
| Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy | |
| Indolent, Recurrent B-cell NHL | |
| Rituximab alone or in combination with cytotoxic agents used in front-line therapy | |
| Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy | |
| Lenalidomide and rituximab | |
| Zanubrutinib and obinutuzumab | |
| EZH2 inhibitor | |
| Bispecific T-cell engagers | |
| CAR T-cell therapy | |
| SCT | |
| Palliative radiation therapy | |
Sources: Radiation therapy · Rituximab with or without chemotherapy · Watchful waiting · Other therapies as designated for patients with advanced-stage disease · Watchful waiting for asymptomatic patients · Rituximab alone or in combination with cytotoxic agents used in front-line therapy · Lenalidomide and rituximab · Maintenance rituximab · Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy · Rituximab alone or in combination with cytotoxic agents used in front-line therapy · Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy · Lenalidomide and rituximab · Zanubrutinib and obinutuzumab · EZH2 inhibitor · Bispecific T-cell engagers · CAR T-cell therapy · SCT · Palliative radiation therapy
Even though existing treatments cure a significant fraction of patients with lymphoma, numerous clinical trials that explore treatment improvements are in progress. If possible, patients can be included in these studies. Standardized guidelines for response assessment have been suggested for use in clinical trials.[2]
Sources: 2
Several retrospective reviews suggest that routine surveillance scans offer little to no value in patients with diffuse-large B-cell lymphoma (DLBCL) who have attained a clinical complete remission after induction therapy. Prognostic value is also difficult to identify for an interim positron emission tomography–computed tomography scan during induction therapy for DLBCL.[3-6]
Active hepatitis B or hepatitis C can be assessed before treatment with rituximab and/or chemotherapy.[7,8] Patients with detectable hepatitis B virus (HBV) benefit from prophylaxis with entecavir in the context of rituximab therapy.[9,10] Patients with a resolved HBV infection (defined as hepatitis B surface antigen-negative but hepatitis B core antibody-positive) are at risk of reactivation of HBV and require monitoring of HBV DNA. In a retrospective study of 326 patients, prophylactic nucleoside analogue therapy lowered HBV reactivation from 10.8% to 2.1%.[11] Similarly, prophylaxis for herpes zoster with acyclovir or valacyclovir and prophylaxis for Pneumocystis with trimethoprim/sulfamethoxazole or dapsone are usually given to patients receiving rituximab with or without combination chemotherapy. Long-term impaired immune health was evaluated in a retrospective cohort study of 21,690 survivors of DLBCL from the California Cancer Registry. Elevated incidence rate ratios were found up to 10 years later for pneumonia (10.8-fold), meningitis (5.3-fold), immunoglobulin deficiency (17.6-fold), and autoimmune cytopenias (12-fold).[12]
Among 2,508 patients in a Danish registry, the incidence of doxorubicin-induced congestive heart failure increased for 115 NHL survivors with a history of cardiac disease (hazard ratio [HR], 2.71; 95% confidence interval [CI], 1.15−6.36) and/or multiple cardiovascular risk factors (HR, 2.86; 95% CI, 1.56−5.23).[13]
Sources: 13
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Although localized presentations are uncommon in B-cell non-Hodgkin lymphoma (NHL), the goal of treatment is to cure the disease in patients with confirmed localized occurrence after undergoing appropriate staging.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for indolent stage I and indolent, contiguous stage II B-cell NHL include:
Radiation therapy.
Sources: Radiation therapy
Rituximab with or without chemotherapy.
Watchful waiting.
Sources: Watchful waiting
Other therapies, as designated for patients with advanced-stage disease.
Sources: Other therapies, as designated for patients with advanced-stage disease
In a prospective randomized trial, 150 patients with stage I or stage II follicular lymphoma were randomly assigned to 30 Gy of involved-field radiation therapy alone or radiation therapy plus six cycles of R-CVP (rituximab, cyclophosphamide, vincristine, prednisolone). With a median follow-up of 9.6 years, the 10-year progression-free survival (PFS) rate favored combined-modality therapy, at 59% (95% confidence interval [CI], 46%–74%) versus 41% for radiation therapy alone (95% CI, 30%–57%) (P = .033). There was no difference in overall survival (OS) (87% and 95%; P = .40).[1][Level of evidence B1]
Sources: 1 · Level of evidence B1
The National Lymphocare Study identified 471 patients with stage I follicular lymphoma. Of those patients, 206 were rigorously staged with a bone marrow aspirate and biopsy, and computed tomography (CT) scans or positron emission tomography (PET)-CT scans.[2] Nonrandomized treatments included radiation therapy (27%), rituximab-chemotherapy (R-chemotherapy) (28%), watchful waiting (17%), R-chemotherapy plus radiation therapy (13%), and rituximab alone (12%), although more than one-third of the patients started with watchful waiting. With a median follow-up of 57 months, PFS favored R-chemotherapy or R-chemotherapy plus radiation therapy, but OS was nearly identical, all over 90%.[2][Level of evidence C2] Clinical trials are required to answer the following questions:[3]
Sources: 2 · 2 · Level of evidence C2 · 3
If the PET-CT scan is clear after excisional biopsy, is watchful waiting or radiation therapy preferred?
Should rituximab be added to radiation therapy for stage I follicular lymphoma?
Is there any role for R-chemotherapy plus radiation therapy?
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Long-term disease control within radiation fields can be achieved in a significant number of patients with indolent stage I or stage II NHL by using radiation therapy. This requires dosages of radiation that usually range from 25 Gy to 40 Gy to involved sites or to extended fields that cover adjacent nodal sites.[1,4-6] Almost one-half of all patients treated with radiation therapy alone will have out-of-field relapse within 10 years.[1,6,7]
A retrospective review of 512 patients from an international consortium evaluated patients with early-stage follicular lymphoma who received at least 24 Gy of localized radiation therapy at initial presentation. With a median follow-up of 52 months, 29.1% of patients developed recurrent lymphoma at a median of 23 months (range, 1−143 months).[8] With a median follow-up of 33 months after relapse, the 3-year OS rate was 91.4% after patients received subsequent systemic chemotherapy that involved rituximab.[8]
Very low-dose radiation therapy with 4 Gy (2 Gy × 2 fractions) can result in 50% remission rates for patients who cannot tolerate higher doses.[9] In a multicenter, randomized, prospective trial, 548 patients with follicular or marginal zone lymphoma received radiation therapy, either 4 Gy in 2 fractions or 24 Gy in 12 fractions.[10]
At a median follow-up of 73.8 months, the 5-year local complete response rate was 89.9% (85.5%–93.1%) after 24 Gy and 70.4% (64.7%–75.4%) after 4 Gy (hazard ratio, 3.46; 95% CI, 2.25–5.33; P < .0001).[10]
Sources: 10
Although durable local control was superior for patients who received 24 Gy, the 4 Gy regimen was nearly comparable with reductions in radiation exposure, time undergoing therapy, and cost.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
When radiation therapy is contraindicated, or when an alternative treatment is preferred, patients with symptomatic disease who require therapy may receive rituximab with or without chemotherapy (as outlined below for more advanced-stage patients).[11] The value of adjuvant treatment with radiation to decrease relapse, plus rituximab (an anti–CD20 monoclonal antibody) either alone or in combination with chemotherapy, has been extrapolated from trials of patients with advanced-stage disease and has not been confirmed.[12,13]
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Watchful waiting can be considered for asymptomatic patients.[14] Watchful waiting has never been compared with up-front radiation therapy in a prospective randomized trial. A retrospective analysis of the Surveillance, Epidemiology and End Results (SEER) Program database in patients diagnosed over a span of 30 years showed improved outcomes for up-front radiation therapy.[15]
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Patients with disease unable to be encompassed by radiation therapy are treated as outlined for patients with stage III or stage IV low-grade lymphoma.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Optimal treatment of advanced stages of low-grade non-Hodgkin lymphoma (NHL) is controversial because current therapeutic options result in low cure rates. Numerous clinical trials are in progress to evaluate treatment issues, and patients are urged to participate. The rate of relapse is fairly constant over time, even in patients who have achieved complete response to treatment. Relapse may occur many years after treatment. Currently, no randomized trials provide guidance to clinicians about the initial choice of watchful waiting, rituximab, nucleoside analogues, alkylating agents, combination chemotherapy, radiolabeled monoclonal antibodies, or combinations of these options.[1]; [2][Level of evidence B1]
Sources: 1 · 2 · Level of evidence B1
For patients with indolent, noncontiguous stage II and stage III NHL, central lymphatic radiation therapy has been proposed but is not usually recommended as a form of treatment.[3,4]
Patients with a resolved hepatitis B virus (HBV) infection (defined as hepatitis B surface antigen-negative but hepatitis B core antibody-positive) are at risk of reactivation of HBV and require monitoring of HBV DNA. In a retrospective study of 326 patients, prophylactic nucleoside analogue therapy lowered HBV reactivation from 10.8% to 2.1%.[5]
Sources: 5
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for indolent, noncontiguous stage II/III/IV B-cell NHL include:
Watchful waiting for asymptomatic patients.
Rituximab alone or in combination with cytotoxic agents used in front-line therapy.
Sources: Rituximab alone or in combination with cytotoxic agents used in front-line therapy
Lenalidomide and rituximab.
Sources: Lenalidomide and rituximab
Maintenance rituximab.
Sources: Maintenance rituximab
Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy.
Sources: Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy
Because none of the therapies listed above are curative for advanced-stage disease, innovative approaches are under clinical evaluation.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Because relapse may occur many years after treatment, even in patients who have achieved complete responses, deferred treatment (i.e., watchful waiting until the patient becomes symptomatic before initiating treatment) can be considered.[2,6-8] The Follicular Lymphoma International Prognostic Index (FLIPI) and the revised FLIPI-2 can predict progression-free survival (PFS) and overall survival (OS), but the scores cannot be used to establish the need for therapy in asymptomatic patients.[9,10]
Evidence (watchful waiting):
Three randomized trials compared watchful waiting with immediate chemotherapy.[7,11]; [12][Level of evidence A1]
Sources: 7 · 11 · 12 · Level of evidence A1
Three randomized trials compared watchful waiting with immediate chemotherapy.[7,11]; [12][Level of evidence A1]
All three trials showed no difference in cause-specific survival or OS.
For patients randomly assigned to watchful waiting, the median time to require therapy was 2 to 3 years. One-third of patients undergoing watchful waiting never required treatment (one-half died of other causes and the other half remained progression free after 10 years).
A selected group of 107 patients with advanced-stage follicular lymphoma were managed with initial watchful waiting; subsequent therapy was delayed for a median of 55 months. These patients achieved equivalent freedom from treatment failure and OS compared with a similar cohort treated immediately with rituximab.[13][Level of evidence C2] This implies that watchful waiting remains a relevant approach even in the rituximab era.
Sources: 13 · Level of evidence C2
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Standard therapy includes rituximab, an anti–CD20 monoclonal antibody, either alone, as was shown in the ECOG-E4402 trial (NCT00075946),[14-19] or in combination with purine nucleoside analogues, such as fludarabine or cladribine, alkylating agents (with or without steroids), or combination chemotherapy. Rituximab may be considered as first-line therapy, either alone or in combination with other agents. Rituximab may be given intravenously (IV) or subcutaneously (SQ), and biosimilar versions, such as CT-P10 and GP2013, have shown equivalent efficacy and safety.[20-22] Combinations include the following:
Sources: ECOG-E4402 · 14 · 19 · 20 · 22
R-F: rituximab + fludarabine.[26]
Sources: 26
R-CHOP: rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.[29-33] A Cochrane meta-analysis could not identify any OS benefit of adding doxorubicin to chemotherapy regimens with rituximab or to chemotherapy regimens without rituximab.[34][Level of evidence A1]
Sources: 29 · 33 · 34 · Level of evidence A1
R-FCM: rituximab + fludarabine + cyclophosphamide + mitoxantrone.[36]
Sources: 36
Evidence (rituximab with or without chemotherapy):
A prospective randomized trial of 534 patients with previously untreated, advanced-stage, follicular lymphoma compared R-CHOP, R-FM, and R-CVP.[29]
Sources: 29
A prospective randomized trial of 534 patients with previously untreated, advanced-stage, follicular lymphoma compared R-CHOP, R-FM, and R-CVP.[29]
With a median follow-up of 84 months, there was no difference in OS (8-year OS rate, 83%; 95% confidence interval [CI], 79%–87%), but the 8-year PFS rates favored R-CHOP (52%) and R-FM (49%) over R-CVP (42%) (P for the three regimens = .037).[29][Level of evidence B1]
Sources: 29 · Level of evidence B1
Four randomized prospective studies of previously untreated patients (involving more than 1,300 patients) and one Cochrane meta-analysis that included both untreated and previously treated patients (involving almost 1,000 patients) have compared rituximab plus combination chemotherapy with chemotherapy alone.[28,33,37]; [38][Level of evidence A1]
Sources: 28 · 33 · 37 · 38 · Level of evidence A1
Four randomized prospective studies of previously untreated patients (involving more than 1,300 patients) and one Cochrane meta-analysis that included both untreated and previously treated patients (involving almost 1,000 patients) have compared rituximab plus combination chemotherapy with chemotherapy alone.[28,33,37]; [38][Level of evidence A1]
Rituximab plus chemotherapy was superior in terms of event-free survival (EFS) or PFS (ranging from 2–3 years) in all of the studies and in terms of OS in all but one study (absolute benefit ranging from 6%–13% at 4 years, P < .04; hazard ratio [HR], 0.63 [0.51–0.79] for the meta-analysis).
All of these trials were performed in symptomatic patients who required therapy. These results do not negate watchful waiting when appropriate.
Fluorine F 18-fludeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) scan status at the completion of rituximab plus chemotherapy induction therapy is strongly predictive of outcome. It is not yet known whether acting on the results of the scans translates into better outcomes.[39,40]
In a prospective randomized trial (NCT00991211), 527 patients with indolent and mantle cell lymphoma were randomly assigned to receive either bendamustine and rituximab or R-CHOP.[24][Level of evidence B1]
Sources: NCT00991211 · 24 · Level of evidence B1
In a prospective randomized trial (NCT00991211), 527 patients with indolent and mantle cell lymphoma were randomly assigned to receive either bendamustine and rituximab or R-CHOP.[24][Level of evidence B1]
With a median follow-up of 45 months, the median PFS favored the bendamustine arm (69 months vs. 31 months [HR, 0.58; 95% CI, 0.44–0.74; P < .0001]) but with no difference in OS.
Compared with the R-CHOP arm, the bendamustine arm was associated with significantly lower rates of alopecia, hematologic toxicity, stomatitis, peripheral neuropathy, and infections.
In a similar prospective randomized trial, 447 patients with indolent and mantle cell lymphoma were assigned to bendamustine and rituximab versus R-CHOP or R-CVP.[25][Level of evidence B1]
Sources: 25 · Level of evidence B1
In a similar prospective randomized trial, 447 patients with indolent and mantle cell lymphoma were assigned to bendamustine and rituximab versus R-CHOP or R-CVP.[25][Level of evidence B1]
With a median follow-up of 65 months, the 5-year PFS rate favored bendamustine and rituximab, 65.5% versus 55.8% (HR, 0.61; 95% CI, 0.45–0.85; P = .0025), but with no difference in OS.
Increased deaths in the bendamustine-and-rituximab arm from cardiovascular causes (seven vs. one) and from secondary malignancies other than lymphoma (five vs. three) may have contributed to the lack of OS advantage.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
The combination of the immunomodulating agent lenalidomide with rituximab (the so-called R2 regimen) has been proposed as an alternative regimen to combinations involving cytotoxic agents and their subsequent short- and long-term toxicities.
Evidence (lenalidomide and rituximab):
In a randomized prospective trial (RELEVANCE [NCT01650701]) of 1,030 patients with previously untreated follicular lymphoma, rituximab plus lenalidomide for 18 months was compared with rituximab plus chemotherapy (usually R-CHOP).[41,42] All patients received rituximab maintenance for up to 2 years.
In a randomized prospective trial (RELEVANCE [NCT01650701]) of 1,030 patients with previously untreated follicular lymphoma, rituximab plus lenalidomide for 18 months was compared with rituximab plus chemotherapy (usually R-CHOP).[41,42] All patients received rituximab maintenance for up to 2 years.
With a median follow-up of 72 months, the 6-year PFS rates (60% and 59%) and 3-year OS rates (89%) were identical (HR for PFS, 1.03; 95% CI, 0.84–1.27; P = .78) (HR for OS was not reported).[41,42][Level of evidence A1]
Sources: 41 · 42 · Level of evidence A1
This trial established that the R2 regimen is as effective as rituximab plus cytotoxic chemotherapy options. The transformation rate to aggressive lymphoma per year was 0.68% in the R2 group and 0.45% in the R-chemotherapy group. With a median follow-up of 72 months, there were no new safety signals.[42]
Sources: 42
In a randomized prospective trial of 358 patients with resistant/refractory indolent lymphoma (usually follicular lymphoma), the R2 regimen was compared with rituximab alone.[43]
Sources: 43
In a randomized prospective trial of 358 patients with resistant/refractory indolent lymphoma (usually follicular lymphoma), the R2 regimen was compared with rituximab alone.[43]
With a median follow-up of 28 months, the median PFS was 39.4 months for R2 and 14.1 months for rituximab alone (P < .0001), with no difference in OS.[43][Level of evidence B1]
Sources: 43 · Level of evidence B1
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
After induction therapy with rituximab only or with rituximab plus chemotherapy, rituximab can be used once every 2 to 3 months as maintenance therapy. Several studies have evaluated this approach.
Evidence (maintenance rituximab for previously untreated patients):
In the PRIMA study (NCT00140582), 1,018 patients with high-risk, previously untreated, symptomatic disease achieved complete response or partial response after induction therapy with immunochemotherapy (usually R-CHOP). Patients were then randomly assigned to 2 years of maintenance rituximab versus no maintenance.[44][Level of evidence B1]
Sources: PRIMA · 44 · Level of evidence B1
In the PRIMA study (NCT00140582), 1,018 patients with high-risk, previously untreated, symptomatic disease achieved complete response or partial response after induction therapy with immunochemotherapy (usually R-CHOP). Patients were then randomly assigned to 2 years of maintenance rituximab versus no maintenance.[44][Level of evidence B1]
With a median follow-up of 9.0 years, median PFS favored rituximab maintenance (10.5 years) compared with observation (4.1 years) (HR, 0.61; 95% CI, 0.52−0.73; P < .001), but with no difference in OS.
In the United Kingdom/International Study (NCT00112931), 379 previously untreated patients with asymptomatic, low-burden disease were randomly assigned to watchful waiting versus rituximab induction only versus rituximab induction followed by 2 years of rituximab maintenance.[45][Level of evidence A3]
Sources: United Kingdom/International Study · 45 · Level of evidence A3
In the United Kingdom/International Study (NCT00112931), 379 previously untreated patients with asymptomatic, low-burden disease were randomly assigned to watchful waiting versus rituximab induction only versus rituximab induction followed by 2 years of rituximab maintenance.[45][Level of evidence A3]
Although OS and histological transformation rates were not different at 3 years, maintenance rituximab was favored based on quality-of-life studies (Mental Adjustment to Cancer Scale P = .0004 at 7 months; Illness Coping Score P = .0012 at 7 months) and time-to-initiation of new treatment by 3 years (54% for watchful waiting vs. 12% for rituximab maintenance [HR, 0.21; 95% CI, 0.14–0.31; P < .0001]).[45][Level of evidence A3]
Sources: 45 · Level of evidence A3
This study suggested that for some patients, watch and wait resulted in watch and worry.[46] However, from the perspective of OS and histological transformation rates, no benefit could be seen with rituximab maintenance.
Sources: 46
In the RESORT study (NCT00075946), 289 previously untreated patients with asymptomatic, low-burden disease were randomly assigned to receive rituximab induction alone, with a re-treatment strategy that used rituximab at relapse versus rituximab induction plus maintenance rituximab every 13 weeks until treatment failure.[47][Level of evidence B3]These three randomized trials in previously untreated patients showed no advantage for the use of rituximab maintenance versus observation and reinduction of therapy at the time of relapse. The trials suggest a benefit for maintenance rituximab after reinduction for relapsed disease. Many questions remain about rituximab maintenance, particularly about truncating therapy at 2 years and long-term safety and efficacy. A trial extending rituximab maintenance to 5 years showed similar EFS or OS versus 1 year of maintenance after induction therapy with rituximab in previously untreated patients.[48][Level of evidence A1]
Sources: RESORT · 47 · Level of evidence B3 · 48 · Level of evidence A1
In the RESORT study (NCT00075946), 289 previously untreated patients with asymptomatic, low-burden disease were randomly assigned to receive rituximab induction alone, with a re-treatment strategy that used rituximab at relapse versus rituximab induction plus maintenance rituximab every 13 weeks until treatment failure.[47][Level of evidence B3]These three randomized trials in previously untreated patients showed no advantage for the use of rituximab maintenance versus observation and reinduction of therapy at the time of relapse. The trials suggest a benefit for maintenance rituximab after reinduction for relapsed disease. Many questions remain about rituximab maintenance, particularly about truncating therapy at 2 years and long-term safety and efficacy. A trial extending rituximab maintenance to 5 years showed similar EFS or OS versus 1 year of maintenance after induction therapy with rituximab in previously untreated patients.[48][Level of evidence A1]
With a median follow-up of 8.7 years, the 7-year rate for freedom from cytotoxic chemotherapy or radiation therapy was 83% for patients who received maintenance rituximab and 63% for patients who received induction alone (HR, 2.37; 95% CI, 1.5–3.8; P = .0001). There was no difference in the 10-year OS rate (83% vs. 84%; nonsignificant P = .5972). A re-treatment strategy achieved comparable disease control using significantly fewer doses of rituximab.
Maintenance rituximab induces prolonged B-cell depletion, but morbidity from infections was not evaluated after 2015, when the full protocol data stopped (12 years after the study began).
The FOLL12 study (NCT02063685) included 807 patients with previously untreated high-tumor burden follicular lymphoma. Patients received rituximab plus chemotherapy induction and were randomly assigned to either standard rituximab maintenance (every 8 weeks for 2 years) or to postinduction treatment (monitoring, rituximab maintenance, or radioimmunotherapy) based on their complete metabolic response and measurable residual disease (MRD)–negative status.[49]
The FOLL12 study (NCT02063685) included 807 patients with previously untreated high-tumor burden follicular lymphoma. Patients received rituximab plus chemotherapy induction and were randomly assigned to either standard rituximab maintenance (every 8 weeks for 2 years) or to postinduction treatment (monitoring, rituximab maintenance, or radioimmunotherapy) based on their complete metabolic response and measurable residual disease (MRD)–negative status.[49]
With a median follow-up of 53 months, the 3-year PFS rate was 86% for patients who received standard maintenance and 72% for patients who received response-based treatment (P < .001). The 3-year OS rate was the same in both groups (98% vs. 97%; P = .238).[49][Level of evidence B1]
Sources: 49 · Level of evidence B1
This trial does not support the use of an end-of-treatment PET-CT scan to guide the use of maintenance rituximab.
A prospective trial included 202 patients with previously untreated low-tumor burden follicular lymphoma. Patients were randomly assigned to receive either four weekly doses of IV rituximab (standard dose, 375 mg/m2) or one dose of IV rituximab followed by three weekly doses of SQ rituximab (1,400 mg) and maintenance doses in months 3, 5, 7, and 9.[19]
Sources: 19
A prospective trial included 202 patients with previously untreated low-tumor burden follicular lymphoma. Patients were randomly assigned to receive either four weekly doses of IV rituximab (standard dose, 375 mg/m2) or one dose of IV rituximab followed by three weekly doses of SQ rituximab (1,400 mg) and maintenance doses in months 3, 5, 7, and 9.[19]
With a median follow-up of 50.2 months, the 4-year PFS rate was 58.1% (95% CI, 47.5%–67.4%) for patients in the SQ arm who received maintenance therapy, and 41.2% (95% CI, 30.6%–51.6%) (HR, 0.585; 0.939–0.871; P = .0076) for the patients in the IV arm who did not receive maintenance therapy.[19][Level of evidence B1]
Sources: 19 · Level of evidence B1
There was no difference in OS or time-to-next treatment.
Outside the context of clinical trials, the use of MRD testing has not been shown to be predictive in directing therapy for patients with follicular lymphoma. In retrospective analyses of two randomized prospective trials, while MRD negativity was prognostic of outcome, maintenance rituximab or obinutuzumab prolonged PFS the most among patients with MRD-negative disease.[49,50][Level of evidence C2] Stopping maintenance rituximab or obinutuzumab was not indicated in patients with MRD-negative disease, negating any possible change in therapy based on that status.
Sources: 49 · 50 · Level of evidence C2
In summary, for previously untreated patients, all of the studies showed improved PFS, with no change in OS.
Evidence (maintenance rituximab for previously treated patients):
In a prospective randomized trial of 465 patients with relapsed follicular lymphoma, responders to R-CHOP or CHOP were further randomly assigned to receive rituximab maintenance (1 dose every 3 months for 2 years) or no maintenance.[51][Level of evidence B1]
Sources: 51 · Level of evidence B1
In a prospective randomized trial of 465 patients with relapsed follicular lymphoma, responders to R-CHOP or CHOP were further randomly assigned to receive rituximab maintenance (1 dose every 3 months for 2 years) or no maintenance.[51][Level of evidence B1]
At a median follow-up of 6 years, rituximab maintenance was better for median PFS (44 months vs. 16 months, P < .001) and borderline for 5-year OS (74% vs. 64%, P = .07).
This benefit for maintenance was evident even for patients who received rituximab during induction therapy. Most patients in both arms received extensive rituximab during postprotocol salvage treatment.
In a prospective randomized trial of 280 patients with relapsed follicular lymphoma, responders to chemotherapy and autologous stem cell transplant consolidation were randomly assigned to receive four doses of rituximab maintenance or no maintenance.[52][Level of evidence B1]
Sources: 52 · Level of evidence B1
In a prospective randomized trial of 280 patients with relapsed follicular lymphoma, responders to chemotherapy and autologous stem cell transplant consolidation were randomly assigned to receive four doses of rituximab maintenance or no maintenance.[52][Level of evidence B1]
With an 8.3-year median follow-up, the 10-year PFS rates favored maintenance (54% vs. 37% [HR, 0.66; 95% CI, 0.47–0.91; P = .012]), but there was no difference in OS.
A meta-analysis of nine randomized clinical trials with a total of 2,586 patients with follicular lymphoma, most of whom had relapsed disease, compared rituximab maintenance with no maintenance and showed improved OS for rituximab maintenance in previously treated patients (HRdeath, 0.72; 95% CI, 0.57–0.91).[53][Level of evidence A1]
Sources: 53 · Level of evidence A1
For previously treated patients, there is more evidence to suggest an OS advantage with the use of rituximab maintenance.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Obinutuzumab is a glycoengineered type II anti–CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity than rituximab.
Evidence (obinutuzumab):
A prospective randomized trial (NCT01332968) of 1,202 patients with previously untreated follicular lymphoma compared obinutuzumab combined with bendamustine (50%), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (33%), or CVP (cyclophosphamide, vincristine, and prednisone) (10%) with rituximab combined with the same chemotherapy regimens (based on investigator choice).[54] After six cycles of combination therapy, patients had 2 years of maintenance therapy, receiving the same antibody every 2 months.Several issues have been raised about this study:In summary, in the absence of any change in OS, switching from rituximab to obinutuzumab in combination with chemotherapy for previously untreated follicular lymphoma is a difficult choice. The PFS differences may be attributable to the imbalance in monoclonal antibody dosing, and the increased side effects and costs are mitigating factors. In this trial, bendamustine combined with either antibody led to unacceptable rates of toxic death.
Sources: NCT01332968 · 54
A prospective randomized trial (NCT01332968) of 1,202 patients with previously untreated follicular lymphoma compared obinutuzumab combined with bendamustine (50%), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) (33%), or CVP (cyclophosphamide, vincristine, and prednisone) (10%) with rituximab combined with the same chemotherapy regimens (based on investigator choice).[54] After six cycles of combination therapy, patients had 2 years of maintenance therapy, receiving the same antibody every 2 months.Several issues have been raised about this study:In summary, in the absence of any change in OS, switching from rituximab to obinutuzumab in combination with chemotherapy for previously untreated follicular lymphoma is a difficult choice. The PFS differences may be attributable to the imbalance in monoclonal antibody dosing, and the increased side effects and costs are mitigating factors. In this trial, bendamustine combined with either antibody led to unacceptable rates of toxic death.
With a median follow-up of 34.5 months, the 3-year PFS rate was 80% in the obinutuzumab group and 73.3% in the rituximab group (HR, 0.66; 95% CI, 0.51–0.85; P = .001).[54][Level of evidence B1]
Sources: 54 · Level of evidence B1
There was no difference in OS.
Compared with what has been seen historically, there was a high rate of toxic deaths among patients using bendamustine in the obinutuzumab arm (5.6%) and in the rituximab arm (4.4%). For patients with indolent low-grade lymphoma, with median survivals exceeding 15 years, the number of toxic deaths during first-line therapy seems excessive. By comparison, the toxic death rate was 1% to 2% when either antibody was combined with CHOP or CVP.
The side effects were significantly higher with obinutuzumab in terms of infusion reactions and subsequent adverse events.
Obinutuzumab costs significantly more than rituximab.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In general, treatment with standard agents rarely produces a cure in patients with relapsed B-cell non-Hodgkin Lymphoma (NHL). Sustained remissions after relapse can often be obtained in patients with indolent lymphomas, but relapse will usually ensue. Favorable survival after relapse has been associated with an age younger than 60 years, complete remission rather than partial remission, and duration of response longer than 2 years.[1] Even patients in the most favorable subset, however, have a tenfold greater mortality compared with age-adjusted U.S. population rates.[2]
Patients who experience a relapse of indolent lymphoma can often achieve disease control with single-agent or combination chemotherapy, rituximab (an anti–CD20 monoclonal antibody), lenalidomide, radiolabeled anti–CD20 monoclonal antibodies, or palliative radiation therapy.[3,4] However, long-term freedom from second relapse is uncommon and multiple relapses usually occur. Patients with indolent lymphoma may experience a relapse with a more aggressive histology. If the clinical pattern of relapse suggests that the disease is behaving in a more aggressive manner, a biopsy can be performed. If a more aggressive histology is confirmed, therapy must change to a regimen applicable to that histological type.[5] Rapid growth or discordant growth between various disease sites may indicate a histological conversion.
In a retrospective review of 325 patients diagnosed between 1972 and 1999, the 10-year risk of histological transformation was 30%.[6] In this series, high-risk factors for subsequent histological transformation were advanced stage, high-risk Follicular Lymphoma International Prognostic Index, and watchful waiting (as opposed to treatment being initiated at diagnosis). The median survival after transformation was 1 to 2 years, with 25% of patients alive at 5 years and with approximately 10% to 20% of patients alive 10 years after re-treatment.[7]
A prospective trial of 631 patients with follicular lymphoma and with a median follow-up of 60 months in the rituximab era (2002–2009) found a 5-year transformation rate to a higher-grade histology of 11%.[8] The median overall survival (OS) after transformation was 50 months, and the 5-year OS rate was 66%, if the transformation occurred more than 18 months after a diagnosis of follicular lymphoma. This series described a better prognosis for patients with transformation than in the era before rituximab.
Sources: 8
For descriptions of the regimens used to treat histological conversions, see the Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma section in Aggressive B-Cell Non-Hodgkin Lymphoma Treatment. The durability of the second remission may be short, and clinical trials can be considered.
Sources: Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Treatment options for indolent, recurrent B-cell NHL include:
Rituximab alone or in combination with cytotoxic agents used in front-line therapy.
Sources: Rituximab alone or in combination with cytotoxic agents used in front-line therapy
Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy.
Sources: Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy
Lenalidomide and rituximab.
Sources: Lenalidomide and rituximab
Zanubrutinib and obinutuzumab.
Sources: Zanubrutinib and obinutuzumab
EZH2 inhibitor.
Sources: EZH2 inhibitor
Bispecific T-cell engagers.
Sources: Bispecific T-cell engagers
Epcoritamab.
Sources: Epcoritamab
Chimeric antigen receptor (CAR) T-cell therapy.
Stem cell transplant (SCT).
Sources: Stem cell transplant (SCT)
Palliative radiation therapy.
Sources: Palliative radiation therapy
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Rituximab results in a 40% to 50% response rate in patients with relapsed indolent B-cell lymphomas.[9-13] Rituximab can also be combined with combination chemotherapy.[14,15]
Evidence (rituximab):
In three randomized, prospective studies involving previously treated patients with relapsed indolent lymphoma, patients were randomly assigned to rituximab maintenance after re-treatment with combination chemotherapy (with or without rituximab during induction) or rituximab alone.[16-18]
In three randomized, prospective studies involving previously treated patients with relapsed indolent lymphoma, patients were randomly assigned to rituximab maintenance after re-treatment with combination chemotherapy (with or without rituximab during induction) or rituximab alone.[16-18]
All trials showed prolongation of response duration.[16-18] One trial with a median follow-up of 39 months demonstrated improvement in median progression-free survival (PFS) (3.7 years vs. 1.3 years, P < .001) and 5-year OS rate (74% vs. 64%, P = .07), favoring maintenance rituximab.[17]
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Obinutuzumab is a CD20-binding monoclonal antibody with alternative epitope binding.
Evidence (obinutuzumab):
A randomized prospective trial (NCT01059630) included 396 patients with rituximab-refractory indolent lymphoma (mostly follicular lymphoma). Patients received obinutuzumab plus bendamustine, followed by obinutuzumab maintenance therapy, for 2 years versus bendamustine alone with no maintenance therapy.[19,20][Level of evidence A1]
Sources: NCT01059630 · 19 · 20 · Level of evidence A1
A randomized prospective trial (NCT01059630) included 396 patients with rituximab-refractory indolent lymphoma (mostly follicular lymphoma). Patients received obinutuzumab plus bendamustine, followed by obinutuzumab maintenance therapy, for 2 years versus bendamustine alone with no maintenance therapy.[19,20][Level of evidence A1]
With a median follow-up of 31.8 months, the 2-year OS rate favored the obinutuzumab combination (74.5% vs. 65.1%) (hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.47–0.96; P = .027). The median PFS also favored the obinutuzumab combination (25.8 months [95% CI, 19.5–41.1] vs. 14.1 months [95% CI, 12.6–16.0]) (HR, 0.57; 95% CI, 0.44–0.73; P < .001).[20][Level of evidence A1]
Sources: 20 · Level of evidence A1
The contribution of maintenance therapy to the outcome could not be assessed in this design.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Responses of 20% to 56% have been reported for lenalidomide, especially in patients with follicular lymphoma and small lymphocytic lymphoma, with even higher responses noted for the combination of lenalidomide and rituximab.[21,22][Level of evidence C3]
Sources: 21 · 22 · Level of evidence C3
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Evidence (zanubrutinib and obinutuzumab):
A randomized, multicenter, phase II study (ROSEWOOD [NCT03332017]) included 217 patients with relapsed or refractory follicular lymphoma after receiving two or more prior lines of therapy. Patients received either the oral Bruton tyrosine kinase inhibitor zanubrutinib plus obinutuzumab or obinutuzumab alone until disease progression.[23][Level of evidence B1]
Sources: ROSEWOOD · 23 · Level of evidence B1
A randomized, multicenter, phase II study (ROSEWOOD [NCT03332017]) included 217 patients with relapsed or refractory follicular lymphoma after receiving two or more prior lines of therapy. Patients received either the oral Bruton tyrosine kinase inhibitor zanubrutinib plus obinutuzumab or obinutuzumab alone until disease progression.[23][Level of evidence B1]
With a median follow-up of 19.0 months, the median PFS was 28.0 months for patients who received zanubrutinib plus obinutuzumab and 10.4 months for patients who received obinutuzumab alone (HR, 0.50; 95% CI, 0.33–0.75; P < .001).
The overall response rate was 69% (95% CI, 61%–76%) in the zanubrutinib-plus-obinutuzumab arm and 46% (95% CI, 34%–58%) in the obinutuzumab-alone arm (P = .0012).
The U.S. Food and Drug Administration approved zanubrutinib and obinutuzumab for patients with relapsed or refractory follicular lymphoma after two or more prior lines of therapy.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Tazemetostat is an inhibitor of EZH2, a histone methyltransferase essential to the formation of lymph node germinal centers, especially with activating variants of EZH2.
Evidence (tazemetostat):
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
Sources: 24
A phase II study included 99 patients with relapsed or refractory follicular lymphoma, 45 of whom had activating EZH2 variants, and 54 of whom had wild-type EZH2.[24]
Treatment with tazemetostat resulted in an objective response rate of 69% (95% CI, 53%–82%) for patients with activating EZH2 variants versus 35% (95% CI, 23%–49%) for patients with wild-type EZH2.[24]
Sources: 24
With a median follow-up of 22 months, the median PFS was 13.8 months (95% CI, 10.7–22.0) for patients with activating EZH2 variants and 11.1 months (95% CI, 3.7–14.6) for patients with wild-type EZH2.[24][Level of evidence C3]
Sources: 24 · Level of evidence C3
Grade 3 or 4 treatment-related adverse events occurred in 4% of patients.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Mosunetuzumab is a bispecific T-cell engager that binds to CD20 and CD3.[25]
Sources: 25
Evidence (mosunetuzumab):
A single-arm, multicenter, phase II study included 90 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy (including an anti-CD20 therapy and an alkylating agent). Patients received mosunetuzumab.[27]
Sources: 27
A single-arm, multicenter, phase II study included 90 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy (including an anti-CD20 therapy and an alkylating agent). Patients received mosunetuzumab.[27]
With a median follow-up of 37.4 months, the objective response rate was 77.8% (95% CI, 67.8%–85.9%), and the complete response rate was 60.0% (95% CI, 49.1%–70.2%), per investigator assessment. The median PFS (per investigator assessment) was 24.0 months. The 3-year OS rate was 82.4% (95% CI, 73.8%–91.0%).[27][Level of evidence C1]
Sources: 27 · Level of evidence C1
Cytokine release syndrome occurred in 44.4% of patients; 97.2% of cases were grade 1 or 2 in severity.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Epcoritamab is a bispecific T-cell engager that binds to CD20 and CD3.
Evidence (epcoritamab):
A single-arm multicenter study (NCT03625037), included 128 patients with relapsed or refractory follicular lymphoma who had received two or more lines of therapy. Patients received epcoritamab.[28]
Sources: NCT03625037 · 28
A single-arm multicenter study (NCT03625037), included 128 patients with relapsed or refractory follicular lymphoma who had received two or more lines of therapy. Patients received epcoritamab.[28]
With a median follow-up of 17.4 months, the overall response rate was 82.0 % (95% CI, 74.3%–88.3%) and the complete response rate was 62.5% (95% CI, 53.5%–70.9%).[28][Level of evidence C3]
Sources: 28 · Level of evidence C3
Only 2% of patients had grade 3 or higher cytokine release syndrome events.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
CAR T-cell therapy, with the autologous anti-CD19 therapeutics axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), or tisagenlecleucel (tisa-cel), has been approved for patients with relapsed follicular lymphoma after two or more lines of prior therapy.
Evidence (CAR T-cell therapy):
In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]
In a phase II trial, 159 patients with relapsed or refractory follicular lymphoma (n = 127), marginal zone lymphoma (n = 31), or diffuse large B-cell lymphoma (n = 1) received axi-cel.[29,30]
With a median follow-up of 41.7 months, the overall response rate was 92% (95% CI, 85%–97%), and the complete response rate was 74%.
The 18-month PFS rate was 64.8% (95% CI, 54.2%–73.5%).[29][Level of evidence C2]
Sources: 29 · Level of evidence C2
The median PFS was 40.2 months for patients with follicular lymphoma and was not reached for patients with marginal zone lymphoma.[30][Level of evidence C2]
Sources: 30 · Level of evidence C2
Cytokine release syndrome occurred in 78% of patients and was grade 3 or 4 in 6% of patients.
Tocilizumab was required in 50% of all patients, and 5% required vasopressors. Grade 3 or 4 neurological events occurred in 15% of patients.
In a phase II trial, 98 patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy received anti-CD19 CAR T-cell therapy with tisa-cel.[31]
Sources: 31
In a phase II trial, 98 patients with relapsed or refractory follicular lymphoma after two or more lines of prior therapy received anti-CD19 CAR T-cell therapy with tisa-cel.[31]
With a median follow-up of 16.6 months, the complete response rate was 69.1% (95% CI, 58.8%–78.3%), and the overall response rate was 86.2% (95% CI, 77.5%–92.4%).[31][Level of evidence C3]
Sources: 31 · Level of evidence C3
Grade 3 or 4 cytokine release syndrome occurred in 48.5% of patients, and 37.1% had grade 3 or 4 neurotoxicity.
A phase II trial (NCT04245839) included 130 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy. Patients had high-risk features (progression of disease within 24 months after first-line chemoimmunotherapy or disease refractory to rituximab and alkylators). Patients received liso-cel.[32]
Sources: NCT04245839 · 32
A phase II trial (NCT04245839) included 130 patients with relapsed or refractory follicular lymphoma who had received two or more prior lines of therapy. Patients had high-risk features (progression of disease within 24 months after first-line chemoimmunotherapy or disease refractory to rituximab and alkylators). Patients received liso-cel.[32]
With a median follow-up of 18.9 months, the overall response rate was 97% (95% CI, 91.6%–99.4%), and the complete response rate was 94% (95% CI, 87.5%–97.8%).[32][Level of evidence C3]
Sources: 32 · Level of evidence C3
Cytokine release syndrome occurred in 56% of patients and was grade 3 or higher in 1% of patients. Neurological side effects occurred in 15% of patients and was grade 3 or higher in 2% of patients.
CAR T cells are being used for high-risk patients whose disease has relapsed rapidly after chemoimmunotherapy. Such an approach is considered in the context of numerous other available agents.
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
In many institutions, autologous or allogeneic SCTs are being used for high-risk patients whose disease has relapsed rapidly after chemoimmunotherapy. Such an approach is considered in the context of numerous other available agents.[33-37]
Evidence (SCT):
The German Low-Grade Lymphoma Study Group treated 307 patients with follicular lymphoma with two cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like induction chemotherapy and then randomly assigned them to receive autologous SCT or interferon maintenance.[38]
Sources: 38
The German Low-Grade Lymphoma Study Group treated 307 patients with follicular lymphoma with two cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like induction chemotherapy and then randomly assigned them to receive autologous SCT or interferon maintenance.[38]
With a median follow-up of 4.2 years, the 5-year PFS rate was 65% for patients who received a transplant versus 33% for patients who received interferon (P < .001). There was no difference in OS.[38][Level of evidence B1]
Sources: 38 · Level of evidence B1
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Palliation may be achieved with very low-dose (4 Gy) involved-field radiation therapy in two fractions for patients with indolent and aggressive relapsed disease.[39] In a prospective randomized trial, treatment with 4 Gy was inferior to treatment with 24 Gy in 12 fractions in PFS (77% vs. 92%, P < .0001).[40][Level of evidence B1]
Sources: 39 · 40 · Level of evidence B1
Source: Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025. Captured 2026-09-09.
Therapy is modeled after the treatment of comparably staged diffuse large cell lymphomas, but the optimal approach remains to be defined.
Lymphoma
ClinicalTrials.gov recordLymphoma
ClinicalTrials.gov recordFollicular Lymphoma
ClinicalTrials.gov recordNon-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas, Marginal Zone Lymphomas
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordNon-Hodgkin's Lymphoma
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordFollicular Lymphoma
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordFollicular Non-Hodgkin's Lymphoma
ClinicalTrials.gov recordWaldenström's Macroglobulinemia
ClinicalTrials.gov recordRelapsed/Refractory Follicular Non-Hodgkin Lymphoma
ClinicalTrials.gov recordFollicular Lymphoma
ClinicalTrials.gov recordAdvanced Follicular Lymphoma
ClinicalTrials.gov recordMarginal Zone Lymphoma, MZL
ClinicalTrials.gov recordLymphoma, Non-Hodgkin
ClinicalTrials.gov recordFollicular Lymphoma, Marginal Zone Lymphoma
ClinicalTrials.gov recordFollicular Lymphoma (FL)
ClinicalTrials.gov recordExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2...
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinaemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordRecurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
ClinicalTrials.gov recordFollicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenström Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenström Macroglobulinemia (WM)
ClinicalTrials.gov recordChronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of...
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenström Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom's Macroglobulinemia
ClinicalTrials.gov recordMarginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia,...
ClinicalTrials.gov recordWaldenström's Macroglobulinemia (WM)
ClinicalTrials.gov recordRecurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph...
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia, DASATINIB
ClinicalTrials.gov recordWaldenstrom Macroglobulinemia, MYD88 Gene Mutation
ClinicalTrials.gov recordOther therapies as designated for patients with advanced-stage disease
Indolent B-Cell Non-Hodgkin Lymphoma
Treatment of Indolent, Recurrent B-Cell Non-Hodgkin Lymphoma
Treatment of Indolent Stage I and Indolent, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma
Treatment of Indolent, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma
BELRAPZO is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin...
DailyMed labelBendamustine Hydrochloride Injection is an alkylating drug indicated for treatment of adult patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established....
DailyMed labelNon-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a...
DailyMed labelBendamustine Hydrochloride Injection is an alkylating drug indicated for treatment of adult patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. (...
DailyMed labelBENDEKA injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell...
DailyMed labelBREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: • adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified...
DailyMed labelEPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated: For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent...
DailyMed labelGAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). ( 1.1 , 14 ) in combination with bendamustine followed...
DailyMed labelLUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under...
DailyMed labelLUNSUMIO VELO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under...
DailyMed labelMONJUVI is a CD19-directed cytolytic antibody indicated: in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL...
DailyMed labelRITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Relapsed or refractory,...
DailyMed labelTAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult...
DailyMed labelTREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin...
DailyMed label1 INDICATIONS & USAGE VIVIMUSTA is an alkylating drug indicated for treatment of patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) •...
DailyMed label1 INDICATIONS & USAGE VIVIMUSTA is an alkylating drug indicated for treatment of patients with: • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) •...
DailyMed label